The King's College London proof-of-concept study in Journal of Medicinal Chemistry introduces Efflux Resistance Breaker (ERB) molecules that embed pump-evasion directly into antibiotic scaffolds, rather than relying on separate inhibitors. Unlike earlier adjuvant strategies that failed in trials due to toxicity and pharmacokinetics mismatches, this chemical redesign keeps intracellular concentrations high enough to restore bactericidal activity. The work is not an RCT or even observational clinical data; it rests on in vitro assays with modest bacterial strain panels and no reported human or animal efficacy metrics, leaving open questions about off-target effects and resistance evolution under selective pressure. Conflicts of interest appear limited to academic and UKHSA affiliations, yet commercialization plans announced by the team warrant scrutiny for future IP-driven bias. Synthesizing this with WHO 2023 AMR data showing 1.27 million direct deaths annually and a 2022 Nature Reviews Microbiology review on AcrAB-TolC pumps, the ERB platform could theoretically salvage fluoroquinolones and tetracyclines already compromised in Gram-negatives. However, the original MedicalXpress coverage underplays the translational gap: efflux is only one resistance layer, and redesign may trade potency for pump avoidance. If scaled, ERB could shift discovery pipelines from de novo agents toward iterative rescue of existing chemical space, but only rigorous preclinical PK/PD and resistance selection studies will determine whether this moves beyond incremental lab success.